P1697: CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE UTILIZATION OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA INITIATING FIRST LINE THERAPY OF ORAL CORTICOSTEROIDS WITH OR WITHOUT RITUXIMAB

• Irina Murakhovskaya,
• Concetta Crivera,
• Ann Leon,
• Evo Alemao,
• Vamshi Ruthwik Anupindi,
• Mitch Dekoven,
• Victoria Divino,
• Iris Lin,
• Cathye Shu,
• Tarek Ebrahim

Affiliations

Irina Murakhovskaya

1 Albert Einstein College of Medicine/Montefiore Medical Center, Department of Hematology and Oncology, Bronx, NY, United States

Concetta Crivera

2 Janssen Global Services, LLC, Horsham, PA, United States

Ann Leon

3 Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA,, United States

Evo Alemao

2 Janssen Global Services, LLC, Horsham, PA, United States

Vamshi Ruthwik Anupindi

4 IQVIA Inc, Falls Church, United States

Mitch Dekoven

4 IQVIA Inc, Falls Church, United States

Victoria Divino

4 IQVIA Inc, Falls Church, United States

Iris Lin

5 Janssen Scientific Affairs, LLC, Horsham, PA, United States

Cathye Shu

6 Janssen Research & Development, LLC, Spring House, PA, USA, United States

Tarek Ebrahim

7 Janssen Pharmaceutical Companies of Johnson & Johnson, Cambridge, MA, United States